Clinical and Experimental Dermatology最新文献_第6页

The utility of interleukin-23 intraclass switching in the treatment of plaque psoriasis: a retrospective review of 43 cases. IL-23类内切换在治疗斑块状银屑病中的效用：对43例病例的回顾性研究。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-12-23 DOI: 10.1093/ced/llae305

M Grace Hren, Sreekar Miriyala, Saakshi Khattri

{"title":"The utility of interleukin-23 intraclass switching in the treatment of plaque psoriasis: a retrospective review of 43 cases.","authors":"M Grace Hren, Sreekar Miriyala, Saakshi Khattri","doi":"10.1093/ced/llae305","DOIUrl":"10.1093/ced/llae305","url":null,"abstract":"Interleukin (IL)-23 inhibitors are a class of injectable biologics, which include risankizumab, tildrakizumab and guselkumab, used for the treatment of moderate-to-severe psoriasis. This retrospective review sought to determine the value of IL-23 inhibitor intraclass switching among patients with psoriasis after they experienced loss of efficacy to any IL-23 inhibitor. We conducted a retrospective chart review, including 43 patients who underwent any of 6 potential iterations of IL-23 intraclass switching between November 2017 and November 2023. Most commonly, patients switched from guselkumab or tildrakizumab to risankizumab (84%). On average, patients failed 2.3 biologic treatments (SD 1.3) prior to switching. Postswitching, 81% of patients achieved an affected body surface area (BSA) < 1% after 248.8 days (SD 126.5). BSA immediately prior to intraclass switch was 13.1 (SD 8.9) [95% confidence interval (CI) 10.4-15.8] and at most recent follow-up was 2.9 (SD 5.2) (95% CI 2.3-5.5). This research adds to a growing body of literature demonstrating the potential of IL-23 intraclass switching in the treatment of moderate-to-severe plaque psoriasis.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"137-140"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bullous drug eruption. 大疱性药疹

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-12-23 DOI: 10.1093/ced/llae294

Dora Mancha, Cláudia Brazão, Lanyu Sun, João Pedro de Vasconcelos, Teresa Correia, Luís Soares-de-Almeida, Paulo Filipe

引用次数: 0

Cosmetic benefit in Mohs surgery: an overemphasized theme? 莫氏手术的美容效果--一个被过分强调的主题？

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-12-23 DOI: 10.1093/ced/llae327

Sibel Demirel, Andrew Affleck

引用次数: 0

Quality-of-life assessment and the impact of early diagnosis and treatment in lichen planopilaris: a systematic review. 扁平苔藓患者的生活质量评估及早期诊断和治疗的影响：系统综述。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-12-23 DOI: 10.1093/ced/llae339

Awatef Kelati, Mohammad Jafferany

引用次数: 0

A large purplish swelling on the arm of a newborn. 新生儿手臂上的大块紫红色肿物。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-12-23 DOI: 10.1093/ced/llae352

Yean Joo Ng, Qi Ji Lai, Henrietta Albela

引用次数: 0

Intravenous low-dose cyclophosphamide pulses followed by rituximab for ocular mucous membrane pemphigoid. 静脉注射小剂量环磷酰胺脉冲后使用利妥昔单抗治疗眼粘膜斑丘疹。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-12-23 DOI: 10.1093/ced/llae316

Myriam Viedma-Martínez, Ricardo Patricio Roman-Cheuque, Alejandro Claudio-Oliva, Antonio Jose Duran-Romero, Jose Francisco Millan-Cayetano, David Jimenez-Gallo, Mario Linares-Barrios

引用次数: 0

Dermatopathology. 皮肤病理学。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-12-23 DOI: 10.1093/ced/llae313

Vidette Wong, Claire Hunter, Helen Louise Hunter

引用次数: 0

Prognostic significance of the systemic immune-inflammation index in patients with Steven-Johnson syndrome and toxic epidermal necrolysis. 史蒂文-约翰逊综合征和中毒性表皮坏死溶解症（SJS/TEN）患者全身免疫炎症指数的预后意义。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-12-23 DOI: 10.1093/ced/llae332

Winn Hui Han, Tobias Tshung En Wong, Ruhana Che Yusof, Rebecca Kai Jan Choong, Shin Shen Yong, Nik Aimee Azizah Faheem, Zhenli Kwan

{"title":"Prognostic significance of the systemic immune-inflammation index in patients with Steven-Johnson syndrome and toxic epidermal necrolysis.","authors":"Winn Hui Han, Tobias Tshung En Wong, Ruhana Che Yusof, Rebecca Kai Jan Choong, Shin Shen Yong, Nik Aimee Azizah Faheem, Zhenli Kwan","doi":"10.1093/ced/llae332","DOIUrl":"10.1093/ced/llae332","url":null,"abstract":"Inflammatory markers such as neutrophil-lymphocyte ratio (NLR) and eosinophil count are known prognostic indicators for the severity of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). This study explores the correlation of systemic immune-inflammation index (SII), platelet-lymphocyte ratio (PLR) and NLR with Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) and patient outcomes. A retrospective audit of 34 patients with SJS/TEN (25 SJS, 3 SJS/TEN overlap, 6 TEN) was conducted from 2018 to 2022. Mean admission values were SII 1597 (SD 1904), NLR 6.52 (SD 5.99) and PLR 202 (SD 135). Cut-off values for predicting mortality were SII 1238 [area under receiver operating characteristic curve (AUROC) 0.82], NLR 8.32 (AUROC 0.80) and PLR 285 (AUROC 0.78). Multiple logistic regression using a backward stepwise method identified SCORTEN as a significant factor associated with mortality (P = 0.03) after adjusting for SII, NLR and PLR. None of the inflammatory markers significantly predicted mortality, although PLR at admission may be a potential risk factor (P = 0.05).","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"141-145"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical sirolimus in dermatology: a systematic review. 皮肤科外用西罗莫司：系统综述。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-12-23 DOI: 10.1093/ced/llae275

Usamah M Afzal, Mohammad Alazemi, Omar Ali, Faisal R Ali, John T Lear

{"title":"Topical sirolimus in dermatology: a systematic review.","authors":"Usamah M Afzal, Mohammad Alazemi, Omar Ali, Faisal R Ali, John T Lear","doi":"10.1093/ced/llae275","DOIUrl":"10.1093/ced/llae275","url":null,"abstract":"Topical sirolimus is increasingly utilized off-licence to manage various dermatological conditions while avoiding typical adverse effects associated with systemic sirolimus. However, widespread use is limited by a highly heterogeneous evidence base of mixed quality. Our aim was to evaluate the current evidence base for the indications, efficacy and safety profile of topical sirolimus in dermatology. A literature search was conducted from 2005 to 4 July 2023, of English-language studies, with the following databases consulted: MEDLINE, PubMed, Embase, CENTRAL and EBSCO. Key words included 'topical', 'rapamycin', 'sirolimus' and 'dermatology'. Data on drug efficacy, concentration, side-effects, cointerventions and follow-up were extracted. The search identified 202 studies, 71 of which met the inclusion criteria. Efficacy of topical sirolimus was demonstrated in facial angiofibromas (799 patients) compared with placebo across multiple randomized controlled trials, with a predominant concentration of 0.1%. Evidence was mixed for use of sirolimus in port-wine stains (61 patients), with evidence of effectiveness for combined sirolimus and pulsed-dye laser. Multiple case reports demonstrated clinical improvement with topical sirolimus in cutaneous vascular abnormalities (33 patients) at a higher concentration of 1%. Other applications of topical sirolimus were predominantly case reports, demonstrating generally favourable outcomes. Topical sirolimus was generally well tolerated; most reported adverse effects were localized irritation and pruritus. Ointment-based preparations and once-daily dosing appeared to confer a better side-effect profile. Most high-quality data pertain to the efficacy of topical sirolimus in treating facial angiofibromas in tuberous sclerosis. Outcomes are generally promising in other indications, with good tolerability, but data quality is mixed.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1-11"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevation of serum carcinoembryonic antigen as a possible predictor of response to pulse methylprednisolone in acquired idiopathic generalized anhidrosis. 血清癌胚抗原（CEA）升高可能是获得性特发性全身性无汗症患者对脉冲甲泼尼龙反应的预测因子

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-12-23 DOI: 10.1093/ced/llae363

Tomoki Sakiyama, Yuichiro Endo, Satoshi Nakamizo, Kenji Kabashima

{"title":"Elevation of serum carcinoembryonic antigen as a possible predictor of response to pulse methylprednisolone in acquired idiopathic generalized anhidrosis.","authors":"Tomoki Sakiyama, Yuichiro Endo, Satoshi Nakamizo, Kenji Kabashima","doi":"10.1093/ced/llae363","DOIUrl":"10.1093/ced/llae363","url":null,"abstract":"Background: Acquired idiopathic generalized anhidrosis (AIGA) is a rare disorder primarily observed in Asian populations, particularly in Japan. Although pulse methylprednisolone therapy is an effective treatment for AIGA, predictors of therapeutic response remain poorly defined.Objectives: To identify factors that predict the efficacy of pulse methylprednisolone therapy in patients with AIGA.Methods: Data obtained from 32 patients with AIGA were assessed based on clinical, histopathological and serological examinations. Statistical analyses were conducted to explore predictors of response to pulse methylprednisolone therapy.Results: The average age of participants was 32.1 years (SD 12.3); 66% were male and 34% female. The response to pulse methylprednisolone therapy was closely associated with the time from the onset to start of therapy (Wilcoxson's rank sum test, P = 0.02, n = 27), with earlier intervention resulting in a better outcome. Notably, male patients and patients presenting with severe symptoms at diagnosis responded better to treatment. High serum carcinoembryonic antigen (CEA) levels and histological evidence of inflammation around sweat glands also correlated with a positive therapeutic response.Conclusions: Earlier intervention, elevated serum CEA levels and inflammation around sweat glands are potential indicators of a successful response to pulse methylprednisolone therapy in patients with AIGA.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"125-129"},"PeriodicalIF":3.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0